Market Access

The company is significantly lowering the US list prices for its popular weight loss and diabetes GLP-1 drugs, signaling a broader shift in pricing strategy as competition intensifies and access pressures grow.

In the second part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, points out how uneven Medicare negotiation timelines between small molecules and biologics are influencing R&D and venture funding decisions, according to biotech investors advocating for legislative changes.

In today’s Pharma Pulse, Johnson & Johnson commits over $1 billion to a new biomanufacturing site in Pennsylvania, while Hims & Hers enters a $1.15 billion agreement to acquire Australian telehealth leader Eucalyptus.

A policy change allowing approval of some new drugs based on one adequate and well-controlled study could accelerate development timelines, while raising questions about evidentiary standards and downstream supply chain planning.

A 2026 industry survey finds mounting pressure from PBMs, federal pricing reforms, and compliance scrutiny, as manufacturers increase automation and AI investment to manage expanding gross-to-net exposure.

While the Inflation Reduction Act introduces a $2,100 out-of-pocket cap and payment smoothing options for Medicare Part D beneficiaries, low awareness and persistent health literacy gaps threaten to limit their real-world impact—highlighting the need for coordinated action across providers, pharmacies, industry, and advocacy groups.

The GLP-1 landscape continues to evolve in both delivery formats and affordability.

In today’s Pharma Pulse, bipartisan lawmakers target PBM vertical integration, while pharma giants race to secure tariff-exempt pricing deals.

Companies not included in the initial round are now pursuing their own agreements amid concerns over levies, Medicare pilot programs, and future price-setting policies.

In today’s Pharma Pulse, a telehealth giant retreats from the weight loss pill conflict, while safety-net hospitals secure a major legal victory against 340B reform.

SQ Innovation’s at-home furosemide injection for heart failure–related edema is now available through two of the Big Three drug wholesalers and covered under a Medicaid rebate agreement, expanding access for hospitals, pharmacies, and eligible patients.

These hubs can streamline access, reduce friction across reimbursement and logistics, and improve outcomes, as the CGT pipeline expands and patient demand accelerates.

TrumpRx is meant to reduce drug costs, but Americans are wondering how it works and what impact it will have.

In today’s Pharma Pulse, TrumpRx officially goes live, while Novo Nordisk prepares to take the oral version of Wegovy to the biggest stage in advertising.

The new platform offers coupon-driven discounts on dozens of high-cost brand name drugs, while raising new questions about eligibility, access, and how savings are applied.

The commercial PBM model is confronting structural strain as market forces—not regulation—begin to expose the fragility of high-rebate pricing economics.

A four-pillar strategy to help ensure both, as copay programs face mounting payer pressure and misuse in 2026.

In today’s Pharma Pulse, the FTC secures a multi-billion-dollar settlement against the "rebate trap," while Congress provides long-term certainty for the digital health revolution.

Policy shifts bring meaningful improvements for some—but looming coverage losses and rising premiums threaten to erase those gains.

A landmark FTC settlement requires Express Scripts to overhaul formulary and rebate practices, boosting price transparency in the process.

CMS’s Globe and Guard models extend MFN pricing into Medicare Part B and Part D, signaling a sweeping shift in US drug pricing policy.

At Trade & Channel Strategies, industry executives explored evolving channel models, serialization challenges, generics and biosimilars, and the strategies shaping pharma's future.

In today’s Pharma Pulse, the biopharma landscape enters a transformative phase as the US signs landmark PBM reforms into law, while Novartis braces for the largest patent expiration cycle in its history.

In today’s Pharma Pulse, HHS issues guidance for manufacturer-direct drug discounts, while clinical data warns of significant weight regain after stopping tirzepatide and semaglutide.

For the first time, CMS has released negotiated prices for high-cost drugs covered under both Medicare Part D and Part B, naming 15 new negotiation targets and signaling continued efforts to rein in prescription drug spending.